Related Experiment Video

Updated: Jun 19, 2025

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

20.7K

The Role of Muscarinic Acetylcholine Receptor M3 in Cardiovascular Diseases

Xinxing Liu1, Yi Yu1, Haiying Zhang1

  • 1Hainan Academy of Medical Sciences, School of Pharmacy, Hainan Medical University, Haikou 571199, China.

International Journal of Molecular Sciences
|July 27, 2024
PubMed

Insights

The muscarinic acetylcholine receptor M3 (M3-mAChR) shows cardioprotective effects, making it a key biomarker for cardiovascular diseases (CVDs). This review explores M3-mAChR

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • The muscarinic acetylcholine receptor M3 (M3-mAChR) plays a critical role in numerous physiological and pathological processes.
  • Specific cardioprotective properties position M3-mAChR as a significant diagnostic and therapeutic biomarker for cardiovascular diseases (CVDs).

Purpose of the Study:

  • To review the expression patterns, functions, and mechanisms of M3-mAChR in the context of cardiovascular diseases.
  • To highlight the potential of M3-mAChR as a therapeutic target for CVDs.

Main Methods:

  • Literature review and synthesis of existing research on M3-mAChR in cardiovascular conditions.
  • Analysis of studies focusing on M3-mAChR's role in cardiac protection and disease development.

Main Results:

  • M3-mAChR is implicated in anti-arrhythmia, anti-hypertrophy, and anti-fibrosis effects, contributing to cardiac protection.
  • Evidence links M3-mAChR to the pathogenesis and progression of various CVDs.
  • The receptor's mechanisms in ischemia/reperfusion injury, cardiac hypertrophy, and heart failure are detailed.

Conclusions:

  • M3-mAChR is a promising target for novel therapeutic strategies in cardiovascular medicine.
  • Understanding M3-mAChR's multifaceted roles opens new avenues for treating CVDs.
Keywords:
cardiomyocytecardiovascular diseasesendothelial cellfibroblastmuscarinic acetylcholine receptor M3

More Related Videos

Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.1K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

15.7K

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
272
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
737
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
712